(Q40715310)

English

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

scientific article published on 6 June 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

1 reference

based on heuristic

inferred from title

author name string

Christophe Massard

1

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Michael S Gordon

2

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Sunil Sharma

3

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Saeed Rafii

4

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Zev A Wainberg

5

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Jason Luke

6

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Tyler J Curiel

7

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Gerardo Colon-Otero

8

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Omid Hamid

9

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Rachel E Sanborn

10

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Peter H O'Donnell

11

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Alexandra Drakaki

12

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Winston Tan

13

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

John F Kurland

14

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Marlon C Rebelatto

15

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Xiaoping Jin

16

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

John A Blake-Haskins

17

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Ashok Gupta

18

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Neil H Segal

19

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

language of work or name

0 references

publication date

6 June 2016

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

34

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

26

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

3119-3125

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

25 September 2017

New Strategies in Bladder Cancer: A Second Coming for Immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

25 September 2017

Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

25 September 2017

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

25 September 2017

Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

25 September 2017

Immunotherapy for non-small-cell lung cancer: the past 10 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

25 September 2017

Toxicities of Immunotherapy for the Practitioner

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

25 September 2017

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

25 September 2017

Immune Checkpoint Blockade in Cancer Therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

25 September 2017

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

25 September 2017

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

25 September 2017

The PD-1 pathway in tolerance and autoimmunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

25 September 2017

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

25 September 2017

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

25 September 2017

Inhibitory B7-family molecules in the tumour microenvironment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

25 September 2017

PD-1 and its ligands in tolerance and immunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

25 September 2017

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

25 September 2017

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

25 September 2017

The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

25 September 2017

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

19 August 2018

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5569690

19 August 2018

Immunotherapy: The development of immunotherapy in urothelial bladder cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/27269937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2016.67.9761

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40715310&oldid=1905027649"